Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences total HIV Franchise Product Sales ($M) ($M)
Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary
Latest, FY2025
20,752
Period ended Dec 31, 2025
Change on a year earlier
+5.8%
19,612 in FY2024
History
9 years
Since FY2017
Sources
7
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total HIV Franchise Product Sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 20,752 | +5.8% | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 19,612 | +7.9% | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 18,175 | +5.7% | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 17,194 | +5.4% | Form 10-K (filed 2025-02-28) ↗ |
| FY2021 | Dec 31, 2021 | 16,315 | -3.7% | Form 10-K (filed 2024-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 16,938 | +3.0% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 16,438 | +12.4% | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 14,627 | +12.4% | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 13,015 | – | Form 8-K (exhibit991earningspressrel.htm, filed 2019-02-04) ↗ |
Breakdown
What makes up total hiv franchise product sales ($m)
- Total HIV Franchise Product Sales — U.S. sales ($M)16,904 · FY2025
- Total HIV Franchise Product Sales — Europe sales ($M)2,392 · FY2025
- Total HIV Franchise Product Sales — Rest of World sales ($M)1,456 · FY2025
- Total HIV Franchise Product Sales — Worldwide YoY growth (%)6.0% · FY2025
- Biktarvy (bictegravir / FTC / TAF) ($M)14,334 · FY2025
- Descovy (FTC / TAF — HIV treatment & PrEP) ($M)2,758 · FY2025
- Genvoya (elvitegravir / cobicistat / FTC / TAF) ($M)1,498 · FY2025
- Odefsey (FTC / rilpivirine / TAF) ($M)1,167 · FY2025
- Symtuza revenue share (darunavir / cobicistat / FTC / TAF) ($M)495 · FY2025
- Other HIV products (incl. Sunlenca & Yeztugo prior to Q1 2026) ($M)500 · FY2025
- Truvada (FTC / TDF — legacy standalone breakout) ($M)114 · FY2023
- Stribild (elvitegravir / cobicistat / FTC / TDF — legacy breakout) ($M)101 · FY2023
- Complera / Eviplera (FTC / rilpivirine / TDF — legacy breakout) ($M)129 · FY2023
- Atripla (efavirenz / FTC / TDF — legacy breakout) ($M)145 · FY2021
Cite this data
StockData. (2026). Gilead Sciences Total HIV Franchise Product Sales ($M) ($M), annual FY2017–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/hiv_total
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.